Tempus AI (TEM) has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca (AZN) and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI’s de-identified oncology data. This partnership is a big win, matching Tempus AI’s fourth-quarter 2024 revenues alone.But with the stock on fire, the big question is, will the rally continue, or is Tempus AI already priced for perfection? Let’s take a closer l ...